EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection

Narittee Sukswai, Joseph D Khoury iD

Current Hematologic Malignancy Reports · 2019-10 · 14 (5) · 368-375

DOI: 10.1007/s11899-019-00533-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Hematologic Malignancy Reports, online erschienen am 23.07.2019. Verfasst von Narittee Sukswai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Immunohistochemistry, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: Immunohistochemistry is an integral technique for tissue-based diagnostics and biomarker detection with broad worldwide adoption. Advances in core chemistries, antibody design, and automation have ushered unprecedented sensitivity, specificity, and reproducibility in immunohistochemistry assays. As a result, clinical immunohistochemistry assays that utilize dual-color approaches and mutation-specific antibodies provide novel tools in clinical diagnostics that until recently were in the realm of investigational research. This review provides an overview of innovations in clinical immunohistochemistry assays with emphasis on those used for patients with hematopoietic neoplasms. RECENT FINDINGS: Advances in clinical-grade immunohistochemistry techniques have allowed labs to develop and validate multiplex assays that improve diagnostic utility-such as CD5/PAX5 and TCF4/CD123 dual-color stains-and have the potential to enhance the specificity of biomarker detection. In addition, the increased availability of immunohistochemistry assays that detect mutant proteins (e.g., BRAF V600E and IDH1 R132H) provides a helpful replacement and/or adjunct for molecular testing. These techniques are highly reproducible, entail reasonable technical and interpretation complexity, and are relatively cost-effective, making them valuable novel tools in modern cancer care. Multiplex and mutation-specific immunohistochemistry assays represent important innovations that provide improved utility in the context of personalized medicine and targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorImmunohistochemistryMolecular Diagnostic TechniquesHematologic NeoplasmsHumansInventionsMutation

Stichwörter der Autor:innen

BRAF V600ECD123Dual immunohistochemistryIDH1LEF1Multiplex immunohistochemistryMutation-specific antibodyPAX5TCF4

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Pathology, Chulalongkorn University, Bangkok, Thailand.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jkhoury@mdanderson.org.

ORCID-Profile: Joseph D Khoury

Zitieren

APA

Sukswai, N., & Khoury, J. D. (2019). Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection. Current Hematologic Malignancy Reports, 14(5), 368-375. https://doi.org/10.1007/s11899-019-00533-9

Vancouver

Sukswai N, Khoury JD. Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection. Current Hematologic Malignancy Reports. 2019;14(5):368-375. doi:10.1007/s11899-019-00533-9

BibTeX
@article{Sukswai2019,
  author = {Sukswai, Narittee and Khoury, Joseph D},
  title = {Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection},
  journal = {Current Hematologic Malignancy Reports},
  year = {2019},
  volume = {14},
  number = {5},
  pages = {368--375},
  doi = {10.1007/s11899-019-00533-9}
}
Kostenlos starten →